GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth
Executive Summary
GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions
You may also be interested in...
GSK/Teva Lamictal settlement
GlaxoSmithKline and Teva reach agreement in principle to settle patent litigation over anti-epileptic Lamictal. Teva filed lamotrigine ANDA in 2002; pediatric exclusivity expires January 2009 (1"The Pink Sheet" Oct. 28, 2002, p. 11)...
GSK/Teva Lamictal settlement
GlaxoSmithKline and Teva reach agreement in principle to settle patent litigation over anti-epileptic Lamictal. Teva filed lamotrigine ANDA in 2002; pediatric exclusivity expires January 2009 (1"The Pink Sheet" Oct. 28, 2002, p. 11)...
GSK Pediarix Price Is $82.54 Per Dose; Coverage Meeting Set For February
GlaxoSmithKline expects the Advisory Committee on Immunization Practices to make a coverage recommendation for the Pediarix combination vaccine during its Feb. 25-26 meeting